Okayama University Research: Plates and Belts: A Toolkit to Prevent Accidental Falls During Invasive Vascular Procedures

In a study reported in Acta Medica Okayama , researchers at Okayama University describe an innovative plate that confines patients to their beds while undergoing vascular procedures thereby preventing unforeseen falls.

Patients undergoing hemodialysis (which requires the regular withdrawal of blood) often need to undergo interventional procedures that keep the blood vessels of the forearm dilated. Percutaneous transluminal angioplasty (PTA), the most common of these procedures, requires a surgeon to visualize microvessels within the arm using an X-ray while the patient lays supine on a motorized bed. Unfortunately, a complication that arises during PTA is the enhanced risk of falls from these elevated beds. Now, Assistant Professor OHARA Toshiaki from Okayama University and colleagues have developed a simple plate-like contraption which secures patients firmly onto their bed while providing the surgeon adequate space for the procedure.

The vascular-access intervention assistance plate — as the innovators named it — is constructed from a durable and cost-effective polymer called polypropylene. The plate is structured to fit under the bed mattress, with a slit for inserting a thick belt that firmly tethers the patient to the bed, at the waist. Additionally, the plate has a lateral protrusion to accommodate and fasten the patient’s arm using a strap. Adjacent to this, a space for placing surgical tools is also provided.

To first calculate the strength of this contraption, plates of varying thickness were simulated to hold loads representative of standard patient weights. The penetration of X-rays through the plates was also verified to confirm that the polymeric material does not interfere with the imaging. Based on the simulations, the thickness of the plate was set at 7 millimeters. The team then looked at real-life patient data to check the device’s effectiveness.

Two groups of patients with similar profiles undergoing angioplasties were analyzed: one group that underwent PTAs without the plate (401 patients) and one with the plate (683 patients). Indeed, the former group had three patients fall, while the latter had none. The researchers also found that signs of dementia, a common cause of accidents and falls, were similar between the two groups. The incidence of falls was thus attributable to the set-up of the procedure and in fact preventable after securing patients to their beds with the plate.

“The vascular-access intervention assistance plate provides good operability and safety, preventing accidental falls in patients undergoing hemodialysis or other procedures,” summarizes the research team. Containing accidental falls is key to preventing further complications in patients undergoing hemodialysis, who are often severely ill and/or old. Introducing the plate into procedures can also enable minimal monitoring of the patient thereby allow medical staff to concentrate primarily on the surgery.

Medical Device News Magazinehttps://infomeddnews.com
Our publication is dedicated to bringing our readers the latest medical device news. We are proud to boast that our subscribers include medical specialists, device industry executives, investors, and other allied health professionals, as well as patients who are interested in researching various medical devices. We hope you find value in our easy-to-read publication and its overall purpose and objectives! Medical Device News Magazine is a division of PTM Healthcare Marketing, Inc. Pauline T. Mayer is the managing editor.

More News!

“These study results are highly encouraging especially given the short treatment duration of 10 days with BX004,” said Jonathan Solomon, Chief Executive Officer of BiomX. “In Part 2 of the study, BX004 showed clinically meaningful improvement in pulmonary function compared to placebo, as measured by relative FEV11 improvement (5.67% at Day 17, 1 week after end of treatment) and Cystic Fibrosis Questionnaire-Revised (CFQ-R) respiratory domain (8.87 points at Day 17) in a predefined subgroup of patients with reduced lung function.”  
Importantly, the study reported no serious treatment-related adverse events from any of the 109 patients treated with InGeneron’s Transpose® RT cell therapy system.
Xeltis, a leading developer of transformative implants that enable the natural creation of living and long-lasting vessels, announces outstanding 12-month data from its first-in-human...
The two presentations were made at the VEITHsymposium, a major vascular surgery conference in New York City. Results showed the HAV had higher rates of patency (blood flow), and lower rates of amputation and infection, compared to historic synthetic graft benchmarks. Humacyte plans to file a Biologics License Application (BLA) for the HAV for an indication in vascular trauma patients with the U.S. Food and Drug Administration (FDA) during the current quarter.
Antengene notes Clinical programs, including ATG-101 (PD-L1/4-1BB bispecific antibody), ATG-022 (Claudin 18.2 antibody-drug conjugate), and ATG-037 (oral CD73 inhibitor) have shown clinical responses in cancer patients with advanced diseases. And ATG-008 (dual mTORC1/2 inhibitor) continued showing strong clinical activities in the Phase II program, with promising efficacy data in cervical cancer patients compared to benchmarks.

By using this website you agree to accept Medical Device News Magazine Privacy Policy